{
  "resourceType": "PlanDefinition",
  "id": "warfarin-nsaids-cds-sign",
  "version": "1.0",
  "name": "PlanDefinition___Warfarin_NSAIDs_Recommendation_Workflow",
  "title": "Warfarin NSAIDs Recommendation",
  "type": {
    "coding": [
      {
        "system": "http://terminology.hl7.org/CodeSystem/plan-definition-type",
        "code": "eca-rule",
        "display": "ECA Rule"
      }
    ]
  },
  "status": "draft",
  "url": "http://hl7.org/fhir/ig/PDDI-CDS/PlanDefinition/warfarin-nsaids-cds-sign",
  "topic": [
    {
      "text": "Warfarin NSAIDs Prescribing"
    }
  ],
  "library": [
    "Library-warfarin-nsaids-cds-sign.json"
  ],
  "extension": [
    {
      "url": "file:///StructureDefinition-pddi-cds-configuration-options.json",
      "extension": [
        {
          "url": "code",
          "valueString": "filter-out-repeated-alerts"
        },
        {
          "url": "type",
          "valueString": "boolean"
        },
        {
          "url": "name",
          "valueString": "Filter out repeated alerts"
        },
        {
          "url": "description",
          "valueString": "Only works if both this configuration option is set to 'true' and  cache-for-order-sign-filtering was set to 'true' in an order-select request. Uses information about this CDS call to filter aparently repititious card. Currently, this only supports filtering out cards that were triggered by the same knowledge artifact when the physician reference display, encounter id, and patient id match between the order-select and order-sign requests."
        }
      ]
    },
    {
      "url": "file:///StructureDefinition-pddi-cds-configuration-options.json",
      "extension": [
        {
          "url": "code",
          "valueString": "alert-non-serious"
        },
        {
          "url": "type",
          "valueString": "boolean"
        },
        {
          "url": "name",
          "valueString": "Alert for non-serious potential drug-drug interactions"
        },
        {
          "url": "description",
          "valueString": "Serious potential drug-drug interactions could result in death; requires hospitalization or extension of hospital stay; results in persistent or significant disability or incapacity; is life-threatening (see https://www.w3.org/2019/05/pddi/index.html). If set to True, this configuration option tells the CDS service to alerts for potential drug-drug interactions that do not meet this criterion."
        }
      ]
    },
    {
      "url": "file:///StructureDefinition-pddi-cds-configuration-options.json",
      "extension": [
        {
          "url": "code",
          "valueString": "show-evidence-support"
        },
        {
          "url": "type",
          "valueString": "boolean"
        },
        {
          "url": "name",
          "valueString": "Show evidence support"
        },
        {
          "url": "description",
          "valueString": "If this options is set to True, CDS response cards will provide more complete information about the evidence that supports the potential drug-drug interaction alert."
        }
      ]
    }
  ],
  "relatedArtifact": [
    {
      "type": "documentation",
      "display": "ワルファリン-NSAIDs 臨床意思決定支援アルゴリズム",
      "url": "https://ddi-cds.org/warfarin-nsaids/"
    }
  ],
  "action": [
    {
      "trigger": [
        {
          "type": "named-event",
          "name": "order-sign"
        }
      ],
      "condition": [
        {
          "kind": "applicability",
          "expression": {
            "language": "text/cql",
            "expression": "Inclusion Criteria"
          }
        }
      ],
      "action": [
        {
          "title": "ワルファリン (製品) と NSAID (製品) の間の潜在的な薬物間相互作用",
          "description": "局所ジクロフェナクの全身吸収は比較的低い. ある研究では, 局所用ジェル（16 g/日）は, 150 mg/日の全身投与で見られる吸収の約 6% をもたらした. 局所ゲルの推奨用量（48 g/日）よりも多い量では, 全身用量の 20% のジクロフェナクが生成された.",
          "condition": [
            {
              "kind": "applicability",
              "expression": {
                "language": "text/cql",
                "expression": "Is context medication topical diclofenac"
              }
            }
          ],
          "dynamicValue": [
            {
              "path": "action.title",
              "expression": {
                "language": "text/cql",
                "expression": "Get Base Summary"
              }
            },
            {
              "path": "activity.extension",
              "expression": {
                "language": "text/cql",
                "expression": "Get Base Indicator"
              }
            }
          ],
          "action": [
            {
              "prefix": "特別な注意事項はない"
            }
          ]
        },
        {
          "title": "ワルファリン (製品) と NSAID (製品) の間の潜在的な薬物間相互作用",
          "description": "出血のリスクが増加する. 出血は, 死亡, 生命を脅かす入院, 障害を引き起こす可能性があるため, 重大な臨床結果を引き起こす可能性がある. 非ステロイド性抗炎症薬 (NSAID) には抗血小板作用があり, ワルファリンなどの経口抗凝固薬と組み合わせると出血リスクが高まる. NSAID の抗血小板効果は, アスピリンの抗血小板効果がアスピリン中止後 2 週間持続するのとは異なり, NSAID が循環中に存在する限り持続する. NSAID は消化性潰瘍を引き起こす可能性もあり, NSAID とワルファリンの併用による出血リスクの増加に関する証拠のほとんどは上部消化管出血 (UGIB) によるもの.",
          "condition": [
            {
              "kind": "applicability",
              "expression": {
                "language": "text/cql",
                "expression": "Is not context medication topical diclofenac"
              }
            }
          ],
          "dynamicValue": [
            {
              "path": "action.title",
              "expression": {
                "language": "text/cql",
                "expression": "Get Base Summary"
              }
            },
            {
              "path": "activity.extension",
              "expression": {
                "language": "text/cql",
                "expression": "Get Base Indicator"
              }
            }
          ],
          "action": [
            {
              "prefix": "リスクを評価し、必要に応じて措置を講じること.",
              "type": {
                "coding": [
                  {
                    "system": "http://terminology.hl7.org/CodeSystem/action-type",
                    "code": "remove"
                  }
                ]
              },
              "description": "凝固作用を高める可能性があるため, アセトアミノフェンを 2 g/日を超える用量で数日間使用する場合は, INR を監視すること. より重度の痛みの場合は, NSAID の代わりに短期オピオイドを検討すること."
            },
            {
              "prefix": "Substitute NSAID (product) with APAP (product).",
              "type": {
                "coding": [
                  {
                    "system": "http://terminology.hl7.org/CodeSystem/action-type",
                    "code": "create"
                  }
                ]
              },
              "description": "APAP を 1 日あたり 2g 未満でオーダー（APAP 500 mg を 4 ～ 6 時間ごとに）.",
              "definitionCanonical": "ActivityDefinition-ad101.json",
              "dynamicValue": [
                {
                  "path": "action.label",
                  "expression": {
                    "language": "text/cql",
                    "expression": "Get Base Label 1"
                  }
                }
              ]
            },
            {
              "prefix": "Substitute NSAID (product) with APAP (product).",
              "type": {
                "coding": [
                  {
                    "system": "http://terminology.hl7.org/CodeSystem/action-type",
                    "code": "create"
                  }
                ]
              },
              "description": "APAP を 1 日あたり 2g 未満でオーダー（APAP 500 mg を 4 ～ 6 時間ごとに）.",
              "definitionCanonical": "ActivityDefinition-ad102.json",
              "dynamicValue": [
                {
                  "path": "action.label",
                  "expression": {
                    "language": "text/cql",
                    "expression": "Get Base Label 2"
                  }
                }
              ]
            }
          ]
        },
        {
          "title": "患者はプロトンポンプ阻害剤（製品）またはミソプロストール（製品）を服用している（または服用していない）.",
          "description": "プロトンポンプ阻害剤とミソプロストールは、NSAID とワルファリンを受けている患者における UGIB のリスクを軽減する可能性がある.",
          "condition": [
            {
              "kind": "applicability",
              "expression": {
                "language": "text/cql",
                "expression": "Is not context medication topical diclofenac"
              }
            }
          ],
          "dynamicValue": [
            {
              "path": "action.title",
              "expression": {
                "language": "text/cql",
                "expression": "Get Card 2 Summary"
              }
            },
            {
              "path": "action.description",
              "expression": {
                "language": "text/cql",
                "expression": "Get Card 2 Detail"
              }
            },
            {
              "path": "activity.extension",
              "expression": {
                "language": "text/cql",
                "expression": "Get Card 2 Indicator"
              }
            }
          ],
          "action": [
            {
              "prefix": "リスクを評価し、必要に応じて措置を講じること.",
              "dynamicValue": [
                {
                  "path": "action.label",
                  "expression": {
                    "language": "text/cql",
                    "expression": "Get Card 2 Label"
                  }
                }
              ]
            }
          ]
        },
        {
          "title": "患者は65歳を超えている（いない）、および/または上部消化管出血の病歴がある（ない）",
          "description": "UGIB または消化性潰瘍の病歴のある患者は, この相互作用により UGIB のリスクが増加する可能性があります. これらの相互作用により, 高齢がUGIBの独立した危険因子となる程度はしっかりと確立されていないが, 一般にUGIBは年齢とともに増加することが知られている.",
          "condition": [
            {
              "kind": "applicability",
              "expression": {
                "language": "text/cql",
                "expression": "Is not context medication topical diclofenac"
              }
            }
          ],
          "dynamicValue": [
            {
              "path": "action.title",
              "expression": {
                "language": "text/cql",
                "expression": "Get Card 3 Summary"
              }
            },
            {
              "path": "action.description",
              "expression": {
                "language": "text/cql",
                "expression": "Get Card 3 Detail"
              }
            },
            {
              "path": "activity.extension",
              "expression": {
                "language": "text/cql",
                "expression": "Get Card 3 Indicator"
              }
            }
          ],
          "action": [
            {
              "prefix": "リスクを評価し、必要に応じて措置を講じること.",
              "dynamicValue": [
                {
                  "path": "action.label",
                  "expression": {
                    "language": "text/cql",
                    "expression": "Get Card 3 Label"
                  }
                }
              ]
            }
          ]
        },
        {
          "title": "患者は全身性コルチコステロイド, アルドステロン拮抗薬, または高用量または複数のNSAIDを同時に服用している（または服用していない）",
          "description": "コルチコステロイドとアルドステロン拮抗薬はどちらも, NSAIDs を服用している患者の UGIB のリスクを大幅に増加させることが示されており, 相対リスクはそれぞれ 12.8 と 11 であり, NSAIDs 単独の場合のリスクは 4.3 である. (Masclee et al. Gastroenterology 2014; 147:784-92.)",
          "condition": [
            {
              "kind": "applicability",
              "expression": {
                "language": "text/cql",
                "expression": "Is not context medication topical diclofenac"
              }
            }
          ],
          "dynamicValue": [
            {
              "path": "action.title",
              "expression": {
                "language": "text/cql",
                "expression": "Get Card 4 Summary"
              }
            },
            {
              "path": "action.description",
              "expression": {
                "language": "text/cql",
                "expression": "Get Card 4 Detail"
              }
            },
            {
              "path": "activity.extension",
              "expression": {
                "language": "text/cql",
                "expression": "Get Card 4 Indicator"
              }
            }
          ],
          "action": [
            {
              "prefix": "リスクを評価し、必要に応じて措置を講じること.",
              "dynamicValue": [
                {
                  "path": "action.label",
                  "expression": {
                    "language": "text/cql",
                    "expression": "Get Card 4 Label"
                  }
                }
              ]
            }
          ]
        }
      ]
    }
  ]
}